Melanoma Coverage from Every Angle
Advertisement
Advertisement

5-Year Outcomes With Trametinib in BRAF V600 E/K–Mutant Melanoma

By: Hillary Ojeda
Posted: Thursday, February 14, 2019

According to a study published in the European Journal of Cancer by Caroline Robert, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, and colleagues, the long-term use of trametinib is a viable option for patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. In addition, based on the 5-year follow-up analysis of the phase III METRIC trial, some patients reaped a long-term survival benefit with the MEK inhibitor.

“The findings from this extended analysis of trametinib monotherapy may serve as the basis for future indirect comparisons against long-term findings from other ongoing trials of dabrafenib and trametinib combination therapy,” the investigators commented.

For this phase III study, the researchers randomly assigned 322 patients in a 2:1 ratio to receive trametinib (2 mg orally, once daily; n = 214) or chemotherapy (dacarbazine [1,000 mg/m2] or paclitaxel [175 mg/m2] intravenously, every 3 weeks; n = 108). They used 5-year outcomes to compare progression-free and overall survival data among the groups.

For the trametinib group, the median progression-free survival was 4.9 months, compared with 1.5 months for the chemotherapy group. “Landmark overall survival rates for trametinib versus chemotherapy arms at 1 year, 2 years, and 5 years were 60.9% versus 49.6%, 32.0% versus 29.4%, and 13.3% versus 17.0%, respectively,” they reported. Because of disease progression with chemotherapy, a total of patients 70 patients (65%) from the chemotherapy group crossed over to the trametinib group early in their treatment.

Disclosure: The study authors’ disclosure information may be found at ejcancer.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.